重症瓣膜疾病的外科治疗研究进展  

Research progress in surgical treatment of severe valvular disease.

作　　者：蒋博一(综述) 刘达兴(审校) JIANG Bo-yi;LIU Da-xing(Affiliated Hospital of Zunyi Medical University,Zunyi 563000,Guizhou,CHINA)

机构地区：[1]遵义医科大学附属医院心血管外科,贵州遵义563000

出　　处：《海南医学》2021年第6期778-781,共4页Hainan Medical Journal

基　　金：贵州省遵义市市级科技计划项目(编号:遵红科合社字[2017]16号)。

摘　　要：随着我国人口老龄化日渐加重以及生活方式的改变,心血管疾病患病率处于持续上升阶段,重症瓣膜疾病发病率也随之升高,严重威胁国民生命健康。随着临床研究的不断深入,在重症瓣膜疾病治疗方法上有新的突破和进展。经导管主动脉瓣置换术(TAVR)、体外膜肺氧合(ECMO)、主动脉内球囊反搏(IABP)、左室辅助装置(LVAD)等治疗方式的出现,为临床危重患者的治疗带来希望。本文主要就重症瓣膜疾病的定义、术前准备、治疗方式等方面进行综述。With the aging of population and the changes in biochemical methods in China,the prevalence of cardiovascular diseases is continuously rising,and the incidence of severe valvular diseases is also increasing,which seriously threatens the lives and health of the people.With the continuous deepening of clinical research,new breakthroughs and progress have been made in the treatment of severe valve diseases.The development of transcatheter aortic valve replacement(TAVR),extracorporeal membrane oxygenation(ECMO),intra-aortic balloon pump(IABP),left ventricular assist device(LVAD)have brought hope for the treatment of clinically critical patients.This article mainly reviews the definition,preoperative preparation,and treatment of severe valvular disease.

关 键 词：重症瓣膜疾病 经导管主动脉瓣置换术 体外膜肺氧合 主动脉内球囊反搏 左室辅助装置 

分 类 号：R654[医药卫生—外科学]